Compass Pathways (NASDAQ:CMPS) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Compass Pathways (NASDAQ:CMPS) from a sell rating to a strong sell rating in a report issued on Monday morning.

A number of other brokerages also recently issued reports on CMPS. Evercore raised shares of Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price objective for the company in a research report on Wednesday, July 8th. BTIG Research lifted their target price on Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research report on Friday, July 17th. Wells Fargo & Company started coverage on Compass Pathways in a report on Monday, July 27th. They set an “equal weight” rating and a $13.00 price target for the company. Finally, Royal Bank Of Canada reduced their price target on Compass Pathways from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.36.

Compass Pathways Price Performance

NASDAQ CMPS opened at $14.20 on Monday. The company has a 50-day moving average price of $12.90 and a 200-day moving average price of $9.88. Compass Pathways has a 52 week low of $4.40 and a 52 week high of $15.40. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $1.97 billion, a P/E ratio of -3.07 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). Equities research analysts anticipate that Compass Pathways will post -1.26 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CMPS. TD Waterhouse Canada Inc. lifted its position in shares of Compass Pathways by 4,292.2% in the second quarter. TD Waterhouse Canada Inc. now owns 30,306 shares of the company’s stock valued at $402,000 after acquiring an additional 29,616 shares in the last quarter. Ancora Advisors LLC bought a new stake in Compass Pathways during the 2nd quarter valued at approximately $43,000. Seven Fleet Capital Management LP lifted its holdings in Compass Pathways by 295.1% in the 1st quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company’s stock worth $874,000 after purchasing an additional 118,021 shares in the last quarter. Parallel Advisors LLC lifted its holdings in Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after purchasing an additional 7,183 shares in the last quarter. Finally, Vivo Capital LLC bought a new position in Compass Pathways in the 1st quarter worth approximately $1,106,000. Institutional investors own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.